Ablynx (ABLYF) Stock Price, News & Analysis

Company Overview

Ablynx was a Belgian biopharmaceutical company focused on discovering and developing therapeutics based on Nanobodies, small antibody-derived proteins designed to bind disease targets with high specificity. Its research programs addressed areas including hematology, immunology, inflammation, oncology and respiratory disease.

The company’s leading product was caplacizumab, a Nanobody-based treatment for acquired thrombotic thrombocytopenic purpura. Caplacizumab was later marketed as Cablivi and became Ablynx’s first approved medicine. Ablynx also developed a pipeline of investigational therapies, including programs targeting immune and inflammatory conditions.

Founded in Belgium, Ablynx conducted research and development activities in Europe and advanced its products through international clinical development and regulatory processes. Sanofi acquired Ablynx in 2018, integrating the company and its Nanobody platform into Sanofi’s broader research and development operations. Edwin Moses served as Ablynx’s chief executive officer during its later independent years.

Key Stats

• Today's Range: $50.63 to $50.63
• 50-Day Range: $50.63 to $50.63
• 52-Week Range: $12.50 to $55.04
• Volume: N/A
• Average Volume: 5,063 shs
• Market Capitalization: $3.81 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:ABLYF
• Previous Symbol: NASDAQ:ABLYF
• CIK: N/A
• Web: www.ablynx.com
• Phone: 329-262-0000
• Fax: N/A
• Employees: N/A
• Year Founded: 2001

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $62.73 million
• Price / Sales: 60.74
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.71 per share
• Price / Book: 18.68

Miscellaneous

• Outstanding Shares: 75,250,000
• Free Float: N/A
• Market Cap: $3.81 billion
• Optionable: Not Optionable
• Beta: 1.99